Du är här

2016-02-23

Vistin Pharma ASA : Solid fourth quarter results and positive market outlook

Norwegian pharmaceutical company Vistin Pharma ASA (OSE: VISTIN) recorded a
solid fourth quarter of 2015. A continued strong market for metformin, a
diabetes type 2 medication, coupled with high volumes in CMO tablet
manufacturing, contributed to the result.

"I am pleased to report on another solid quarter for Vistin Pharma. Demand for
our metformin products exceeds our current production capacity, while our CMO
business continues to perform according to plan. We are still experiencing
price pressure in the opioids market, but the long term outlook remains
favourable", says CEO Kjell-Erik Nordby.

Vistin Pharma recorded revenue and other income of NOK 104.5 million in the
fourth quarter. Reported EBITDA was NOK 16.1 million, while the underlying
EBITDA adjusted for one-off items was NOK 7.4 million. Net profit in the
fourth quarter was NOK 10.3 million, while the full year* (1 June - 31
December) net result was NOK 21.4 million.

With solid, long-term potential in all business segments, Vistin Pharma's
ambition is to grow the Company significantly.

"We are currently undertaking a feasibility study for capacity expansion of
our metformin plant. At the same time an ongoing operational excellence
programme within our CMO business aims to increase our current tablet
production capacity significantly. In parallel with these initiatives, we
continue to monitor the market for potential M&A candidates", says Nordby.

Vistin Pharma will give a presentation today at 08:30 CET at Felix
Konferansesenter, Bryggetorget 3, Oslo, Norway. CEO Kjell-Erik Nordby and CFO
Gunnar Manum will represent the company. The presentation will be held in
English.

The presentation will be webcast live and can be accessed directly
fromhttp://webtv.hegnar.no/presentation.php?webcastId=29501459,orhttp://www.....

Please find the report and presentation for the fourth quarter 2015 enclosed.
The report and presentation will also be made available onwww.vistin.com.

For further information, please contact:

Kjell-Erik Nordby
CEO
+47 91 36 42 80

kjell-erik.nordby@vistin.com

Gunnar Manum
CFO
+47 95 17 91 90

gunnar.manum@vistin.com

* Note: Vistin Pharma ASA was established in February 2015, and the Group had
no operating activities prior to Vistin Pharma AS' acquisition of the B2B
business and tablet production assets from Weifa AS on 1 June 2015.

About Vistin Pharma

Vistin Pharma is a Norwegian pharmaceutical company producing Active
Pharmaceutical Ingredients (APIs) and solid dosage forms for the global
pharmaceutical industry. The company has key positions in the Metformin and
Opioids markets, and a strong foundation for creating a highly efficient
Contract Manufacturing tablet production (CMO) business. Solid growth
potentials exist in all the business segments.

With more than 75 years of pharmaceutical industry experience, Vistin Pharma
has built significant capacity and expertise as an API provider. The Company
has more than 140 highly qualified employees and two manufacturing facilities
in Kragerø, Norway. Both facilities are certified according to current Good
Manufacturing Practice (cGMP) and successfully inspected by the US Food and
Drug Administration (FDA) in 2014. Vistin Pharma's headquarter is in Oslo,
Norway.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Vistin Pharma ASA fourth quarter presentation 2015
http://hugin.info/168869/R/1988164/729926.pdf
Vistin Pharma ASA fourth quarter report 2015
http://hugin.info/168869/R/1988164/729925.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vistin Pharma ASA via Globenewswire

HUG#1988164

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.